 |
|
fosamprenavir |
|
Detailed Prescribing Information |
| Dosing Forms | 700 mg tablets, 50 mg/ml liquid |
| Dosing |
Without boosting:
2x700 mg twice a day with or without food With boosting: 2 x 700 mg + ritonavir 1-2 x 100 mg, both once a day (for patients who are relatively antiretroviral naive only - specifically without protease inhibitor mutations) or 1x700 mg + ritonavir 1x100 mg, both twice a day; use 3x100 mg ritonavir with concomitant efavirenz |
| Hepatic impairment: reduce dose to 1x700 twice a day in hepatic impairment (Pugh score 5-8) | |
| Food dependence | Fosamprenavir may be taken with or without food. |
| Adverse Effects |
Diarrhea, nausea & vomiting,
rash Also perioral paresthesia, hepatitis, fat redistribution, hyperlipidemia, Type 2 diabetes |
| Contraindications |
Rifampin (decreases
fosamprenavir levels by up to 80%) Fosamprenavir should not be used in severe hepatic impairment (Pugh score 9-12) |
| Interactions |
Fosamprenavir levels are
decreased by efavirenz (use boosted dosing above) Fosamprenavir levels are increased by delavirdine Fosamprenavir decreases lopinavir levels by 60% and fosamprenavir levels are decreased by up to 70% by lopinavir |
| No data: nevirapine, atazanavir (June 2004) | |
| Suggested laboratory evaluations | Liver profile and glucose monthly x 3 months, then every 3-4 months; lipid profile q3-4 months |
| Warnings |
Concomitant lopinavir/ritonavir
(Kaletra) is not recommended due to decreased and possibly subtherapeutic lopinavir levels that
result. There appears to be a chance of cross-hypersensitivity with sulfonamides (16% vs 14% incidence of reaction in persons with a history of sulfonamide hypersensitivity fosamprenavir vs placebo, respectively) |
| Usage Suggestions |
This drug may largely supplant
amprenavir due to decreased pill burden and better tolerance. Fosamprenavir was approved for pediatric use in 2007.1 |
| Full Prescribing Information | http://www.lexiva.com |
| Links to Antiretroviral Sections (click on anything) |
| Nucleoside & Nucleotide Reverse Transcriptase Inhibitors (NRTI) & NNRTI/NRTI Combinations |
| AZT | ddC | ddI | d4T | 3TC | ABC | FTC | TDF | Combivir | Trizivir | Epzicom | Truvada | Atripla |
| Nonnucleoside Reverse Transcriptase Inhibitors (NNRTI) |
| efavirenz | nevirapine | delavirdine |
| Protease Inhibitors (PI) | Boosted Protease Inhibitors |
| saquinavir | indinavir | ritonavir | nelfinavir | amprenavir | lopinavir + ritonavir | atazanavir | fosamprenavir | tipranavir |
| Fusion Inhibitors |
| enfuvirtide |
Updated 1.11.2008